In addition, a significant proportion of histologically assessed GBMs samples are at risk of being under-graded 25 and the evaluation of the HER2 expression in breast cancers is often subject to equivocal results 26, which may complicate treatment decisions and negatively impact prognosis. The gene discussed is ERBB2; the disease is breast carcinoma.